Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study.

Unmanaged pharmacogenomic and drug interaction risk can lengthen hospitalization and may have influenced the severe health outcomes seen in some COVID-19 patients. To determine if unmanaged pharmacogenomic and drug interaction risks were associated with longer lengths of stay (LOS) among patients hospitalized with COVID-19, we retrospectively reviewed medical and pharmacy claims from 6025 Medicare Advantage members hospitalized with COVID-19. Patients with a moderate or high pharmacogenetic interaction probability (PIP), which indicates the likelihood that testing would identify one or more clinically actionable gene-drug or gene-drug-drug interactions, were hospitalized for 9% (CI: 4-15%; p < 0.001) and 16% longer (CI: 8-24%; p < 0.001), respectively, compared to those with low PIP. Risk adjustment factor (RAF) score, a commonly used measure of disease burden, was not associated with LOS. High PIP was significantly associated with 12-22% longer LOS compared to low PIP in patients with hypertension, hyperlipidemia, diabetes, or chronic obstructive pulmonary disease (COPD). A greater drug-drug interaction risk was associated with 10% longer LOS among patients with two or three chronic conditions. Thus, unmanaged pharmacogenomic risk was associated with longer LOS in these patients and managing this risk has the potential to reduce LOS in severely ill patients, especially those with chronic conditions.

Optimization of aeromedical base locations in New Mexico using a model that considers crash nodes and paths.

In a recent paper, Tokar Erdemir et al. (2008) introduce models for service systems with service requests originating from both nodes and paths. We demonstrate how to apply and extend their approach to an aeromedical base location application, with specific focus on the state of New Mexico (NM). The current aeromedical base locations of NM are selected without considering motor vehicle crash paths. Crash paths are the roads on which crashes occur, where each road segment has a weight signifying relative crash occurrence. We analyze the loss in accident coverage and location error for current aeromedical base locations. We also provide insights on the relevance of considering crash paths when selecting aeromedical base locations. Additionally, we look briefly at some of the tradeoff issues in locating additional trauma centers vs. additional aeromedical bases in the current aeromedical system of NM. Not surprisingly, tradeoff analysis shows that by locating additional aeromedical bases, we always attain the required coverage level with a lower cost than with locating additional trauma centers.